CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 17, 2023 at 02:19 am EDT
Share
CrystalGenomics Invites Co., LTD. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 84.21 million compared to KRW 110.41 million a year ago. Net loss was KRW 33,964.07 million compared to KRW 6,013.05 million a year ago. Basic loss per share from continuing operations was KRW 473 compared to KRW 87 a year ago. Diluted loss per share from continuing operations was KRW 473 compared to KRW 87 a year ago. Basic loss per share was KRW 473 compared to KRW 87 a year ago.
For the six months, sales was KRW 355.32 million compared to KRW 280.17 million a year ago. Net loss was KRW 38,438.37 million compared to KRW 8,838.28 million a year ago. Basic loss per share from continuing operations was KRW 536 compared to KRW 128 a year ago. Diluted loss per share from continuing operations was KRW 536 compared to KRW 128 a year ago. Basic loss per share was KRW 536 compared to KRW 128 a year ago.
CG Invites Co Ltd is a Korea-based company principally engaged in the development and manufacturing of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical Research and Development segment is engaged in the research, development and sale of new drugs such as anti-inflammatory painkillers, anticancer drugs, anti-infectives and others. It is also engaged in the real estate rental business. The Pharmaceutical Manufacturing segment is engaged in the manufacture, retail and wholesale of finished drug products. The Other segment is engaged in the manufacture and sale of hot packs and other household items.
CRYSTALGENOMICS INVITES CO., LTD. 
